Stockscreener 앱 받기
0.00
100.00%
-53.01
전일 마감가:
$53.01
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$2.76B
수익:
$285.01M
순이익/손실:
$95.63M
주가수익비율:
0.00
EPS:
1.762
순현금흐름:
$105.42M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$89.12
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
0.00 | 2.76B | 285.01M | 95.63M | 105.42M | 1.762 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-07 | 개시 | Goldman | Buy |
| 2025-08-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews
Price to earnings forward of Soleno Therapeutics Inc – LS:A3DS0P - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation | Press Release - Stockhouse
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (SLNO) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Soleno Therapeutics (SLNO) Q4 2025 earnings summary - Quartr
Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary - Quartr
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Steady Performance with Limited Upside in the Biotech Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire
Soleno Therapeutics Inc. Investors with Substantial Losses Have O - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Stable Horizon with Strong Cash Reserves - DirectorsTalk Interviews
How Soleno Therapeutics Inc. (SLNO) Affects Rotational Strategy Timing - Stock Traders Daily
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirt - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire
2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect | Press Release - Stockhouse
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating the Biotech Sector with a Strong Free Cash Flow - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Soleno Therapeutics Inc (SLNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Soleno Therapeutics Inc (SLNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire
2026-06-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect | Press Release - Stockhouse
Soleno Therapeutics Inc (SLNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Evaluating The Biotech's Steady Trajectory - DirectorsTalk Interviews
3-year VYKAT XR trial eases hyperphagia, behaviors in PWS - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory - DirectorsTalk Interviews
SLNO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Soleno Therapeutics (SLNO) Holds Steady at $53.01: Consolidation Within Key BoundariesFactor Crowding - newsline.com
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact - TradingView
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating Zero Upside but Strong Cash Flow - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out - ACCESS Newswire
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.60%
0.04%
자본화:
|
볼륨(24시간):